The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr. Philip Dormitzer, may have “conspired to withhold public

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the development of the company’s Covid-19 vaccine was purposefully delayed until after the 2020 presidential election.

A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations provided by a rival drugmaker.

The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots. Moderna (MRNA) and Pfizer (PFE) shares move higher on this news, while Novavax (NVAX) takes a dip.

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The U.S. Food and Drug Administration (FDA) has officially approved a COVID-19 vaccine from Novavax for adults 65 and older and for individuals ages 12 to 64 who have an underlying health condition that puts them at higher risk for serious illness from a coronavirus infection.

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for use in anyone 12 and older. What's the change?

Novavax Inc. drew retail attention on Friday after receiving a Biologics License Application for its COVID-19 vaccine, Nuvaxovid, from the U.S. Food and Drug Administration. Novavax shares closed at $6.